Bide Pharmatech (SH:688073)2024-10-23 09:18Financial Performance - The company's operating revenue for Q3 2024 was ¥279,170,579.63, a decrease of 1.14% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥32,014,828.25, an increase of 8.20% year-on-year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 17.19% to ¥24,134,070.37 in Q3 2024[2] - Basic and diluted earnings per share for Q3 2024 were both ¥0.35, an increase of 6.06% year-on-year[2] - The net profit attributable to shareholders for the year-to-date decreased by 26.05% to ¥83,853,892.80[2] - The net profit for Q3 2024 was CNY 83,853,892.80, a decrease of 25.4% compared to CNY 112,647,629.62 in Q3 2023[17] - The total profit for Q3 2024 was CNY 102,391,559.79, down from CNY 131,930,720.44 in the same period last year, reflecting a decline of 22.5%[17] - The basic and diluted earnings per share for Q3 2024 were both CNY 0.94, compared to CNY 1.25 in Q3 2023, indicating a decrease of 24.8%[18] - The company reported a net profit of RMB 228,562,036.21 for the first three quarters of 2024, up from RMB 224,586,657.91 in the same period of 2023, indicating a growth of about 1.3%[14] Research and Development - The total R&D investment for Q3 2024 was ¥15,473,117.51, an increase of 7.70% year-on-year, representing 5.54% of operating revenue[4] - Research and development expenses rose to RMB 45,523,716.19, compared to RMB 41,143,681.30 in the previous year, reflecting a growth of approximately 10.5%[16] Assets and Liabilities - The total assets at the end of Q3 2024 were ¥2,352,165,412.90, a decrease of 2.60% from the end of the previous year[4] - The total assets of the company amounted to RMB 2,352,165,412.90, a decrease from RMB 2,415,027,980.82 in the previous period[14] - Non-current liabilities totaled RMB 38,185,293.35, down from RMB 50,515,725.61, showing a reduction of approximately 24.3%[14] - The total liabilities of the company were RMB 354,192,484.46, compared to RMB 325,485,828.49, reflecting an increase of about 8.8%[14] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥100,549,955.37, with no applicable percentage change[2] - Cash flow from operating activities for the first three quarters of 2024 was CNY 100,549,955.37, a significant improvement from a cash outflow of CNY 122,873,122.85 in the same period last year[20] - The company reported cash inflows from operating activities totaling CNY 889,986,877.02, compared to CNY 841,311,762.23 in the previous year, representing an increase of 5.8%[19] - Cash outflows for operating activities were CNY 789,436,921.65, down from CNY 964,184,885.08 in Q3 2023, showing a reduction of 18.1%[20] - The net cash flow from investment activities was CNY -349,749,621.69, worsening from CNY -61,549,997.46 in the same period last year[20] Shareholder Information - The top shareholder, Dai Lan, holds 32.64% of the shares, while the second-largest shareholder, Dai Long, holds 14.42%[10] - The company has no significant changes in the participation of major shareholders in margin trading or securities lending activities[10] - The report indicates that there are no significant related party transactions among the shareholders, except for the relationship between Dai Lan and Dai Long, who are siblings[10] Market and Product Development - The company has not reported any new product launches or technological advancements during this quarter[11] - There are no updates on market expansion or mergers and acquisitions in the current report[11] - The company has not provided any specific guidance for future performance or outlook in this quarter's report[11] Comprehensive Income - The company’s total comprehensive income for Q3 2024 was CNY 87,226,599.54, down from CNY 104,028,617.61 in Q3 2023, a decline of 16.1%[18] - The company recorded other comprehensive income after tax of CNY 3,372,706.74, a recovery from a loss of CNY 8,619,012.01 in the previous year[17] Inventory and Current Assets - The total current assets decreased to approximately RMB 2.16 billion from RMB 2.26 billion, reflecting a reduction of about 4.4%[12] - Inventory levels increased slightly to approximately RMB 709.92 million from RMB 699.43 million, indicating a growth of about 1.9%[12] - The company's accounts receivable stood at approximately RMB 229.31 million, a slight decrease from RMB 235.01 million, showing a decline of about 2.4%[12] Cash and Cash Equivalents - As of September 30, 2024, the company's cash and cash equivalents amounted to approximately RMB 889.36 million, a decrease from RMB 1,274.08 million as of December 31, 2023, representing a decline of about 30.3%[12] - The cash and cash equivalents at the end of Q3 2024 stood at CNY 878,913,439.70, compared to CNY 1,183,792,938.94 at the end of Q3 2023, a decrease of 25.7%[21] - The company's cash and cash equivalents increased to RMB 58,390,582.00 from RMB 231,234.01, indicating a significant rise in liquidity[14]